Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | GERN |
---|---|---|
09:32 ET | 54597 | 4.1499 |
09:34 ET | 18402 | 4.12 |
09:36 ET | 11322 | 4.13 |
09:38 ET | 37795 | 4.135 |
09:39 ET | 6963 | 4.145 |
09:41 ET | 4890 | 4.15 |
09:43 ET | 4185 | 4.155 |
09:45 ET | 1109 | 4.155 |
09:48 ET | 4200 | 4.15 |
09:50 ET | 13965 | 4.135 |
09:52 ET | 5000 | 4.135 |
09:54 ET | 173398 | 4.118 |
09:56 ET | 30593 | 4.15 |
09:57 ET | 4360 | 4.15 |
09:59 ET | 11014 | 4.15 |
10:01 ET | 9265 | 4.155 |
10:03 ET | 5482 | 4.15 |
10:06 ET | 11580 | 4.155 |
10:08 ET | 8535 | 4.155 |
10:10 ET | 5578 | 4.165 |
10:12 ET | 4440 | 4.17 |
10:14 ET | 3813 | 4.185 |
10:15 ET | 1716 | 4.185 |
10:17 ET | 2726 | 4.19 |
10:19 ET | 26224 | 4.18 |
10:21 ET | 6501 | 4.18 |
10:24 ET | 6754 | 4.17 |
10:26 ET | 2835 | 4.175 |
10:28 ET | 883 | 4.17 |
10:30 ET | 12987 | 4.165 |
10:32 ET | 1200 | 4.16 |
10:33 ET | 25405 | 4.16 |
10:35 ET | 36612 | 4.155 |
10:37 ET | 3154 | 4.16 |
10:39 ET | 4669 | 4.155 |
10:42 ET | 12509 | 4.135 |
10:44 ET | 2949 | 4.13 |
10:46 ET | 15466 | 4.135 |
10:48 ET | 12327 | 4.135 |
10:50 ET | 6860 | 4.145 |
10:51 ET | 1453 | 4.14 |
10:53 ET | 1448 | 4.14 |
10:55 ET | 2057 | 4.145 |
10:57 ET | 800 | 4.145 |
11:00 ET | 1969 | 4.145 |
11:02 ET | 8945 | 4.135 |
11:04 ET | 14162 | 4.125 |
11:06 ET | 4074 | 4.125 |
11:08 ET | 4324 | 4.12 |
11:09 ET | 20767 | 4.135 |
11:11 ET | 10547 | 4.135 |
11:13 ET | 972 | 4.135 |
11:15 ET | 11574 | 4.13 |
11:18 ET | 13747 | 4.12 |
11:20 ET | 15171 | 4.125 |
11:22 ET | 16201 | 4.1397 |
11:24 ET | 41598 | 4.143295 |
11:26 ET | 410768 | 4.125 |
11:27 ET | 1639 | 4.125 |
11:29 ET | 5953 | 4.12 |
11:31 ET | 3944 | 4.125 |
11:33 ET | 14743 | 4.135 |
11:36 ET | 6440 | 4.135 |
11:38 ET | 9108 | 4.145 |
11:40 ET | 2583 | 4.15 |
11:42 ET | 1924 | 4.145 |
11:44 ET | 2399 | 4.145 |
11:45 ET | 6000 | 4.145 |
11:47 ET | 400 | 4.145 |
11:49 ET | 1685 | 4.145 |
11:51 ET | 4754 | 4.145 |
11:54 ET | 3450 | 4.145 |
11:56 ET | 1533 | 4.14 |
11:58 ET | 1700 | 4.145 |
12:00 ET | 2410 | 4.145 |
12:02 ET | 5128 | 4.145 |
12:03 ET | 7559 | 4.155 |
12:05 ET | 36549 | 4.15 |
12:07 ET | 6638 | 4.145 |
12:09 ET | 5805 | 4.145 |
12:12 ET | 2604 | 4.14 |
12:14 ET | 770 | 4.145 |
12:16 ET | 6731 | 4.145 |
12:18 ET | 7385 | 4.145 |
12:20 ET | 11028 | 4.155 |
12:21 ET | 8261 | 4.155 |
12:23 ET | 5100 | 4.15 |
12:25 ET | 625 | 4.155 |
12:27 ET | 5878 | 4.15 |
12:30 ET | 624 | 4.155 |
12:32 ET | 543 | 4.155 |
12:34 ET | 1589 | 4.155 |
12:36 ET | 2276 | 4.15 |
12:38 ET | 12545 | 4.145 |
12:39 ET | 750 | 4.14 |
12:41 ET | 891 | 4.145 |
12:43 ET | 1373 | 4.14 |
12:45 ET | 2285 | 4.145 |
12:48 ET | 6202 | 4.13 |
12:50 ET | 9822 | 4.115 |
12:52 ET | 13145 | 4.125 |
12:54 ET | 1724 | 4.125 |
12:56 ET | 2479 | 4.125 |
12:57 ET | 1998 | 4.125 |
12:59 ET | 1480 | 4.125 |
01:01 ET | 750 | 4.1282 |
01:03 ET | 2734 | 4.12 |
01:06 ET | 2876 | 4.125 |
01:08 ET | 10495 | 4.125 |
01:10 ET | 14331 | 4.11 |
01:12 ET | 10938 | 4.125 |
01:14 ET | 11295 | 4.115 |
01:15 ET | 1995 | 4.115 |
01:17 ET | 700 | 4.115 |
01:19 ET | 2743 | 4.115 |
01:21 ET | 3671 | 4.11 |
01:24 ET | 12453 | 4.125 |
01:26 ET | 8166 | 4.125 |
01:28 ET | 11138 | 4.115 |
01:30 ET | 4861 | 4.11 |
01:32 ET | 6431 | 4.115 |
01:33 ET | 6605 | 4.11 |
01:35 ET | 5327 | 4.115 |
01:37 ET | 4444 | 4.115 |
01:39 ET | 44879 | 4.125 |
01:42 ET | 2532 | 4.125 |
01:44 ET | 2950 | 4.12 |
01:46 ET | 14584 | 4.125 |
01:48 ET | 7116 | 4.125 |
01:50 ET | 1999 | 4.125 |
01:51 ET | 4490 | 4.125 |
01:53 ET | 7970 | 4.125 |
01:55 ET | 4406 | 4.125 |
01:57 ET | 54474 | 4.125 |
02:00 ET | 40676 | 4.135 |
02:02 ET | 31916 | 4.13 |
02:04 ET | 2563 | 4.13 |
02:06 ET | 18288 | 4.125 |
02:08 ET | 17604 | 4.13 |
02:09 ET | 11094 | 4.13 |
02:11 ET | 6052 | 4.13 |
02:13 ET | 55090 | 4.115 |
02:15 ET | 35425 | 4.115 |
02:18 ET | 50408 | 4.115 |
02:20 ET | 45229 | 4.105 |
02:22 ET | 3476 | 4.105 |
02:24 ET | 19605 | 4.09 |
02:26 ET | 2159 | 4.095 |
02:27 ET | 1011 | 4.095 |
02:29 ET | 32802 | 4.085 |
02:31 ET | 3025 | 4.08 |
02:33 ET | 14949 | 4.095 |
02:36 ET | 4208 | 4.095 |
02:38 ET | 4943 | 4.09 |
02:40 ET | 700 | 4.095 |
02:42 ET | 14213 | 4.085 |
02:44 ET | 5280 | 4.085 |
02:45 ET | 11955 | 4.085 |
02:47 ET | 4881 | 4.085 |
02:49 ET | 10086 | 4.09 |
02:51 ET | 76697 | 4.085 |
02:54 ET | 31059 | 4.095 |
02:56 ET | 27162 | 4.09 |
02:58 ET | 525 | 4.09 |
03:00 ET | 2042 | 4.09 |
03:02 ET | 400 | 4.095 |
03:03 ET | 900 | 4.095 |
03:05 ET | 14397 | 4.0801 |
03:07 ET | 2825 | 4.085 |
03:09 ET | 7460 | 4.09 |
03:12 ET | 2013 | 4.095 |
03:14 ET | 308497 | 4.115 |
03:16 ET | 20290 | 4.12 |
03:18 ET | 2370 | 4.12 |
03:20 ET | 2212 | 4.13 |
03:21 ET | 3938 | 4.125 |
03:23 ET | 7844 | 4.125 |
03:25 ET | 5006 | 4.12 |
03:27 ET | 9630 | 4.12 |
03:30 ET | 11267 | 4.115 |
03:32 ET | 25233 | 4.115 |
03:34 ET | 23060 | 4.125 |
03:36 ET | 26071 | 4.11 |
03:38 ET | 18336 | 4.115 |
03:39 ET | 19930 | 4.115 |
03:41 ET | 10305 | 4.12 |
03:43 ET | 4300 | 4.115 |
03:45 ET | 4198 | 4.115 |
03:48 ET | 45926 | 4.115 |
03:50 ET | 11385 | 4.115 |
03:52 ET | 36539 | 4.115 |
03:54 ET | 53710 | 4.105 |
03:56 ET | 165387 | 4.095 |
03:57 ET | 66946 | 4.11 |
03:59 ET | 1090766 | 4.11 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Geron Corp | 2.5B | -11.4x | --- |
CG Oncology Inc | 2.4B | -30.4x | --- |
IDEAYA Biosciences Inc | 2.5B | -12.9x | --- |
Longboard Pharmaceuticals Inc | 2.3B | -27.6x | --- |
Scholar Rock Holding Corp | 2.7B | -12.8x | --- |
Keros Therapeutics Inc | 2.2B | -11.3x | --- |
Geron Corporation is a late-stage clinical biopharmaceutical company developing investigational first-in-class telomerase inhibitor, imetelstat, to treat hematologic malignancies. The Company is engaged in the development of therapeutic products for oncology. Its lead indication for imetelstat is in Low or Intermediate-1 risk myelodysplastic syndromes. It is developing imetelstat for the treatment of several myeloid hematologic malignancies, including a Phase 3 clinical trial, named IMpactMF, in relapsed/refractory myelofibrosis (MF) with overall survival as the primary endpoint, that is enrolling patients. It is also conducting a Phase 1 combination therapy clinical trial, named IMproveMF, in first-line Intermediate-1, Intermediate-2 or High-Risk myelofibrosis, or frontline MF, that is enrolling patients and imetelstat is being studied in an investigator-led Phase 2 clinical trial, named IMpress, in Intermediate-2 or High-Risk myelodysplastic syndromes and acute myeloid leukemia.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $2.5B |
---|---|
Revenue (TTM) | $1.4M |
Shares Outstanding | 602.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.50 |
EPS | $-0.36 |
Book Value | $0.46 |
P/E Ratio | -11.4x |
Price/Sales (TTM) | 1,822.0 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -16,559.94% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.